对于神经退行性疾病的 лютеолин:一篇综述
Dunuvilla Kavindi Jayawickreme1, Cletus Ekwosi1, Apurva Anand1
1Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
Pharmacological reports : PR
|June 21, 2024
概括
在临床前研究中,一种天然的黄胺 (flavonoid) - - 丁醇 (luteolin) - - 在预防阿尔茨海默氏症和帕金森症等神经退行性疾病方面显示出有前途. 然而,需要更多的临床研究来证实它对人类的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 像阿尔茨海默氏症和帕金森症这样的神经退行性疾病 (NDD) 影响全球数百万人.
- 目前对NDD的治疗主要是症状性的,并没有解决潜在的原因.
- 具有神经保护性质的天然化合物正在作为辅助疗法进行研究.
研究的目的:
- 在各种神经退行性疾病模型中审查卢铁对神经保护作用的临床前证据.
- 为了总结黄素的抗炎,抗氧化和神经保护作用.
- 评估黄素作为NDD治疗剂的潜力.
主要方法:
- 在体外和体内临床前研究的系统审查.
- 在阿尔茨海默病,帕金森病,亨廷顿病和多发性硬化症的模型中分析了对黄素影响的研究.
- 评估科学报告关于黄素的抗炎和抗氧化特性.
主要成果:
- 氨酸在临床前模型中显示出显著的抗炎,抗氧化和神经保护作用.
- 广泛的研究突出显示了luteolin在阿尔茨海默病模型中的益处.
- 证据还支持黄素在帕金森病模型中的神经保护作用,对亨廷顿病和多发性硬化症的研究有限.
结论:
- 临床前研究表明,黄素具有针对各种神经退行性疾病的显著神经保护潜力.
- 素的抗炎和抗氧化特性有助于其神经保护作用.
- 进一步的临床试验至关重要,以确定黄素在人类神经退行性疾病中的治疗疗效.
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524


